Phase I trial of PCNU administered by 5-day courses

R. H. Earhart, J. M. Koeller, H. L. Davis

    Research output: Contribution to journalArticlepeer-review

    6 Scopus citations


    PCNU was selected for clinical trials based on high activity in both standard and intracisternally transplanted murine tumors. PCNU was administered to 24 patients with refractory advanced solid tumors by courses of five daily iv injection every 6 weeks. The total dose ranged from 25 to 125 mg/m2/course. The major dose-limiting toxicity was reversible thrombocytopenia, with the nadir at 28-49 days and recovery by 2 weeks later. At a dose of 125 mg/m2/course, the mean nadir platelet count was 77 x 103/mm3 (range, 16-201 x 103/mm3). Recovery time was prolonged with successive course in four patients, suggesting cumulative toxicity. The mean nadir of leukopenia at this dose was 2.6 x 103 cells/mm3 (range, 1.2-5.0 x 103 cells/mm3) and tended to occur with a later median at day 44. Nausea and vomiting were unusually mild for a nitrosourea. Sporadic transaminasemia and elevated LDH may have been related to the vehicle, N,N'-dimethylacetamide. Other major organ toxic effects were not encountered, and there were no objective responses. PCNU was found to be a base-substitution mutagen in the Salmonella typhimurium assay. A starting dose of 125 mg/m2, divided into five daily doses, is suggested for phase II trials in patients with no significant hematologic compromise from prior chemotherapy or radiation, and a dose of 75 mg/m2 is recommended for all others.

    Original languageEnglish (US)
    Pages (from-to)835-840
    Number of pages6
    JournalCancer Treatment Reports
    Issue number9-10
    StatePublished - Jan 1 1981

    ASJC Scopus subject areas

    • Oncology
    • Cancer Research


    Dive into the research topics of 'Phase I trial of PCNU administered by 5-day courses'. Together they form a unique fingerprint.

    Cite this